187 related articles for article (PubMed ID: 26852132)
21. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
22. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer.
Faneyte IF; Kristel PM; van de Vijver MJ
Anticancer Res; 2004; 24(5A):2931-9. PubMed ID: 15517899
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells.
Yu SL; Lee DC; Son JW; Park CG; Lee HY; Kang J
Oncol Rep; 2013 Sep; 30(3):1293-300. PubMed ID: 23817620
[TBL] [Abstract][Full Text] [Related]
25. Chromatin regulators mediate anthracycline sensitivity in breast cancer.
Seoane JA; Kirkland JG; Caswell-Jin JL; Crabtree GR; Curtis C
Nat Med; 2019 Nov; 25(11):1721-1727. PubMed ID: 31700186
[TBL] [Abstract][Full Text] [Related]
26. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
[TBL] [Abstract][Full Text] [Related]
27. [Anthracyclines in the adjuvant treatment of breast carcinoma: thirty years later].
Lopez M
Clin Ter; 2006; 157(2):165-77. PubMed ID: 16817507
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
[TBL] [Abstract][Full Text] [Related]
29. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
30. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
[TBL] [Abstract][Full Text] [Related]
31. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
32. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
33. FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
Xing M; Wang J; Yang Q; Wang Y; Li J; Xiong J; Zhou S
Cancer Chemother Pharmacol; 2019 Oct; 84(4):861-872. PubMed ID: 31428819
[TBL] [Abstract][Full Text] [Related]
34. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
Meisenberg C; Ashour ME; El-Shafie L; Liao C; Hodgson A; Pilborough A; Khurram SA; Downs JA; Ward SE; El-Khamisy SF
Nucleic Acids Res; 2017 Feb; 45(3):1159-1176. PubMed ID: 28180300
[TBL] [Abstract][Full Text] [Related]
37. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
38. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.
Xie X; Hu Y; Xu L; Fu Y; Tu J; Zhao H; Zhang S; Hong R; Gu X
Tumour Biol; 2015 Sep; 36(9):7185-94. PubMed ID: 25894378
[TBL] [Abstract][Full Text] [Related]
39. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
[TBL] [Abstract][Full Text] [Related]
40. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
